Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of PF-04965842 with or without topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis
CTR20181769Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started May 2019; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20181769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181769.